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LETTERS TO 
FLUOXETINE INDUCED AKATHISIA AND 
SUICIDALLY 
Sir, 
Dr. S. Haque Nizamie & P.N. Suresh 
Kumar in their article 'fluoxetine induced 
extrapyramidal symptoms: Case reports' in 
Indian Journal of Psychiatry 1998, Vol. 1,No. 1, 
87-89 have categorically remarked absence of 
suicidal ideation in both the cases who had 
developed pseudoparkinsonism and akathisia 
while being treated with fluoxetine alone and in 
combination with heloperidol & lithium. Akathisia 
had appeared in these cases on 5th day in easel 
and 6th & 14th day in case 2 respectively. The 
absence of suicidal ideation has been attributed 
to early detection and treatment of akathisia. 
The development of akathisia and emergence/ 
aggravation of suicidality is a complex issue. 
Suicidal ideation has been observed with anti 
depressant pharmacotherapy and has not been 
proved to be associated with any specific type 
of antidepressant. Whether certain anti 
depressants precipitate and or aggravate suicidal 
ideation in a subgroup of patients, responder as 
well as non responder to therapy is uncertain. It 
is unrelated to the dosage of fluoxetine (Mann & 
Kapur,1991). Suicidal ideation has been 
observed appearing suddenly, concurrent with 
neuroleptic induced akathisia and disappeared 
when akathisia was treated (Drake & Ehrlich, 
1985). Fluoxetine induced akathisia is 
indistinguishable from that of neuroleptic induced 
akathisia (Lipinski et al., 1989). The proposed 
link between f'uoxetine induced akathisia and 
suicidality is explained on the basis of four 
neuron model of extrapyramidal motor system, 
in which increased serotonin activity by inhibiting 
the nigrostriatal dopamine tract, is capable of 
inducing a syndrome named Extra Pyramidal 
Dysphoric Reactions, one extreme form of 
manifestation of which is suicidal ideation 
(Hamilton & Opler,1992). I would like to raise a 
question and request for comments from the 
author on severity of akathisia and its relation to 
suicidality, which is lacking in the present case 
reports. Suicidality may be related to severity of 
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akathisia rather than its duration. 
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RISPERIDONE IN INDIAN PATIENTS WITH 
SCHIZOPHRENIA 
Sir, 
We read with intrest the study by 
Agarwal etal.(1998) titled 'Risperidone in Indian 
patients with Schizophrenia'. Limitations of an 
open-label study not withstanding, this study has 
a few shortcomings which we would like to 
mention. 
First, the patients entering the study 
were rated on Positive and Negative Symptom 
Scale (PANSS) after a week's wash-out period. 
A more meaningful approach would have been 
to rate the patients at first contact while they 
were still on medication and then a week after 
wash-out. This enables an investigator to know 
whether withdrawal from neuroleptics contributed 
to any improvement in symptomatology. It is 
known that many patients under routine clinical 
treatment actually benefit from a reduction in 
their medication dose rather than an increase 
(Johnson & Johnson,1995). This may be 
particularly true in patients with extrapyramidal 
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symptoms (EPS) in whom reduction in EPS 
would have caused decrease in secondary 
negative symptoms. 
Second, the study did not distinguish 
primary from secondary negative symptoms. 
This assumes significance in view of the authors' 
conclusion that risperidone is effective in 
ameliorating negative symptoms whereas 
currently there is little evidence to substantiate 
an independent effect of any of the atypical 
antipsychotics, including clozapine on primary 
negative symptomatology (King, 1998). 
Third, it is not mentioned whether the 
study was carried out on stable patients or 
patients having an acute exacerbation. In acute 
psychotic episodes an improvement in negative 
symptoms may be secondary to improvement 
in positive symptoms, thus eluding the 
investigator from knowing the true effect of the 
antipsychotic on negative symptoms (McPhillips 
& Barnes, 1997). A study carried out on patients 
maintained on stable neuroleptic regimes is more 
representative of a measure of improvement in 
negative symptoms on introducing a new 
antipsychotic drug. 
Fourth, 22% of the patients prior to the 
beginning of the study had EPS and following 
treatment with risperidone this figure rose to 
65%. Risperidone causes least EPS at doses 
less than 6 mg per day and its adverse effects 
increase in a dose-dependent fashion (Schooler, 
1994). In this trial, patients were treated at two 
fixed doses - 6 mg per day and 8 mg per day. It 
is possible that patients with 8 mg per day 
schedule may have contributed more 
significantly towards this increase in the overall 
EPS figure than the other group. Hence, a break-
up of incidence of EPS between the two groups 
would have been more informative. Furthermore, 
it is not specified whether the patients were on 
anticholinergics or not before entering the trial 
or whether the anticholinergics too were stopped 
during the wash-out phase. Patients maintained 
on anticholinergics would obviously have more 
EPS once this medication was stopped which 
may explain the increase in the incidence of EPS 
after treatment with risperidone. 
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Another point pertaining to adverse 
effects with risperidone is that initial titration with 
risperidone does cause autonomic instability in 
25% cases (Buckley & Meltzer, 1995). This may, 
in part explain the increase in autonomic adverse 
effects after initiation of risperidone. 
Fifth, the study uses a fixed-dose design 
which is not practical in a clinical setting. Also 
worth mentioning here is that the trial uses the 
commonly practised regime of hiking risperidone 
by 2 mg per day till 6 mg per day on day 3. This 
may be too rapid a titration as has been 
suggested by a study (Luchins et al., 1998). Thus, 
in future trials a comparison of adverse effects 
between this regime and a more gradual one 
would provide clinically relevant information on 
the tolerability of risperidone. 
Lastly, authors conclude that risperidone 
is effective for both positive and negative symptoms 
in Indian patients with schizophrenia. While the 
efficacy of risperidone for positive symptoms is no 
doubt a proven one, that for negative symptoms 
appears mostly confined to secondary negative 
symptoms (King,1998). Accounting for an 
antipsychotic's efficacy for primary negative 
symptomatology requires more rigorous double-
blind placebo-controlled trials the recommendations 
for which have been spelt out (Moller, 1995). 
Nevertheless, a study of such a 
magnitude deserves applause and is without 
reservations, a landmark in context of 
psychopharmacology in India. This trial would 
foster further research with risperidone especially 
in chronic patients with primary, enduring 
negative symptoms maintained on stable 
neuroleptic regimes. 
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REPLY 
Sir, 
Kindly refer to the comments of Duggal 
and Nizamie on our paper. We are grateful to 
them for the interest shown in our paper. Our 
responses to their comments are given below-
I. The commetators have suggested that the 
PANSS should have been administered 
before and after the wash-out period. This has been 
clearly stated in the methodology section that 
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PANSS was done before and after wash-out and 
people showing 20% improvement were dropped. 
2. The concept of primary and secondary 
negative symptoms is still evolving and at the 
time the study was undertaken in 1996 this issue 
has not yet crystalised. That is why no attempt 
was made to differentiate primary from 
secondary negative symptoms. 
3. This study was done on patient consulting 
the clinic, on specified days and fulfilling the 
inclusion and exclusion criteria. Stability of 
symptomatology was not a criteria. However, 
chronic schizophrenic patients who had acute 
exacerbation were excluded. It has been also 
clearly stated in methodology thus the patients 
were more or less stable. 
4. There were 71 patients on 8 mg & 28 
(37%) of them developed EPS whereas, 
75 patients were on 6 mg & 37 (49%) developed 
EPS. Thus the dose of 6 and 8 mg did not show 
much difference on development of EPS in these 
patients. US/Canada study, also showed that 
patients on risperidone need same amount of 
anticholenergics as patients on haloperidol. 
5. Dose escalation was done as per 
recommended protocol at that time. It is possible 
that increase in autonomic instability was due to 
this reason. 
6. Clinical drug trial do recommend flexible 
dose design. In this study fixed dose design was 
used to study the acceptability of two 
recommended dosage. Earlier studies on 
risperidone have also used fixed dose design. 
The conclusions of any study have to 
be interpreted keeping in mind the strength and 
weaknesses of the study. A good study should 
allow readers to make independent conclusions. 
A.K. AGARWAL, MD.DPM.Head, Department of Psychiatry, 
KGs Medical College, Lucknow . 
RISPERIDONE INDUCED DYSTONIC 
REACTION AND AKATHISIA 
Sir, 
P.N. Suresh Kumar has reported acute 
dystonic reaction and akathisia in a patient who 
was given risperidone 3 rng b.i.d. in early part of 
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